Skip to content
Regeneron
-
Regeneron partners with Tessera Therapeutics in USD275M deal to develop gene writing therapy for AATD
Regeneron is investing USD 150 million in equity and upfront payments to acquire half of the global development and commercialization rights for TSRA-196.